Immunohistochemical Expression of Vascular Endothelial Growth Factor in Ovarian Surface Epithelial Neoplasms and its Association with Histological Type, Grade, Clinical Stage and Tumour Metastasis
Introduction: Ovarian carcinoma is one of the most common gynaecologic cancers and remains the leading cause of death as the patients are diagnosed at the advanced stage of the disease. Vascular Endothelial Growth Factor (VEGF), a promoter of angiogenesis, participates in multiple mechanisms to prom...
Ausführliche Beschreibung
Autor*in: |
Asaranti Kar [verfasserIn] Debasmita Das [verfasserIn] Bhagyalaxmi Nayak [verfasserIn] Pallavi Bhuyan [verfasserIn] Sasmita Panda [verfasserIn] Tushar Kar [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2021 |
---|
Schlagwörter: |
---|
Übergeordnetes Werk: |
In: Journal of Clinical and Diagnostic Research - JCDR Research and Publications Private Limited, 2009, 15(2021), 10, Seite EC24-EC28 |
---|---|
Übergeordnetes Werk: |
volume:15 ; year:2021 ; number:10 ; pages:EC24-EC28 |
Links: |
Link aufrufen |
---|
DOI / URN: |
10.7860/JCDR/2021/49501.15533 |
---|
Katalog-ID: |
DOAJ007611137 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | DOAJ007611137 | ||
003 | DE-627 | ||
005 | 20230502113843.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.7860/JCDR/2021/49501.15533 |2 doi | |
035 | |a (DE-627)DOAJ007611137 | ||
035 | |a (DE-599)DOAJ7c71bd9fb2a04965a7736b7ad76e4eb2 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 0 | |a Asaranti Kar |e verfasserin |4 aut | |
245 | 1 | 0 | |a Immunohistochemical Expression of Vascular Endothelial Growth Factor in Ovarian Surface Epithelial Neoplasms and its Association with Histological Type, Grade, Clinical Stage and Tumour Metastasis |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Introduction: Ovarian carcinoma is one of the most common gynaecologic cancers and remains the leading cause of death as the patients are diagnosed at the advanced stage of the disease. Vascular Endothelial Growth Factor (VEGF), a promoter of angiogenesis, participates in multiple mechanisms to promote ovarian cancer cell growth, angiopoiesis and distant metastasis. So, it is a promising target for antiangiogenic therapy in management and downstaging of ovarian cancer. Aim: To evaluate the immunohistochemical expression of VEGF in different surface epithelial neoplasms of ovary and compare it with histological type, grade and stage in malignant cases. Materials and Methods: This was an observational cross-sectional study conducted from August 2018 to January 2020. Total 50 consecutive cases of surface epithelial ovarian neoplasms received in Pathology Department of Srirama Chandra Bhanja (SCB) Medical College, Cuttack were examined for expression of VEGF by Immunohistochemistry (IHC). Data was examined to find association of VEGF expression with demographic profile, grade, stage and were analysed statistically using Statistical Package for the Social Sciences (SPSS) software version 21.0. Statistical significance was tested by using Pearson’s chi-square test. The p<0.05 was considered significant. Results: Total 50 cases of ovarian surface epithelial neoplasms of different types and grade were included in the study. A 42 of the 50 cases (84%) showed VEGF expression. Out of the 42 positive cases, 18 were high VEGF expressors and 24 were low VEGF expressors. The VEGF expression was significantly higher in carcinomas as compared to benign and borderline neoplasms and also in high grade malignancies in comparison to low grade (p≤0.001). Conclusion: The study shows that the differential expression of VEGF in different ovarian epithelial neoplasms which can be a diagnostic and prognostic tool and can be applied as a VEGF targeted therapy in certain group of patients. | ||
650 | 4 | |a angiogenesis | |
650 | 4 | |a immunohistochemistry | |
650 | 4 | |a ovarian epithelial tumours | |
650 | 4 | |a targeted therapy | |
653 | 0 | |a Medicine | |
653 | 0 | |a R | |
700 | 0 | |a Debasmita Das |e verfasserin |4 aut | |
700 | 0 | |a Bhagyalaxmi Nayak |e verfasserin |4 aut | |
700 | 0 | |a Pallavi Bhuyan |e verfasserin |4 aut | |
700 | 0 | |a Sasmita Panda |e verfasserin |4 aut | |
700 | 0 | |a Tushar Kar |e verfasserin |4 aut | |
773 | 0 | 8 | |i In |t Journal of Clinical and Diagnostic Research |d JCDR Research and Publications Private Limited, 2009 |g 15(2021), 10, Seite EC24-EC28 |w (DE-627)789478048 |w (DE-600)2775283-5 |x 0973709X |7 nnns |
773 | 1 | 8 | |g volume:15 |g year:2021 |g number:10 |g pages:EC24-EC28 |
856 | 4 | 0 | |u https://doi.org/10.7860/JCDR/2021/49501.15533 |z kostenfrei |
856 | 4 | 0 | |u https://doaj.org/article/7c71bd9fb2a04965a7736b7ad76e4eb2 |z kostenfrei |
856 | 4 | 0 | |u https://jcdr.net/articles/PDF/15533/49501_CE[Ra1]_F[SH]_PF1(JY_RK)_PFA(SC_SS)_PN(KM).pdf |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/2249-782X |y Journal toc |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/0973-709X |y Journal toc |z kostenfrei |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_DOAJ | ||
912 | |a SSG-OLC-PHA | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_63 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_170 | ||
912 | |a GBV_ILN_206 | ||
912 | |a GBV_ILN_213 | ||
912 | |a GBV_ILN_230 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_2005 | ||
912 | |a GBV_ILN_2009 | ||
912 | |a GBV_ILN_2011 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_2055 | ||
912 | |a GBV_ILN_2111 | ||
912 | |a GBV_ILN_4012 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4126 | ||
912 | |a GBV_ILN_4249 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4307 | ||
912 | |a GBV_ILN_4313 | ||
912 | |a GBV_ILN_4322 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4324 | ||
912 | |a GBV_ILN_4325 | ||
912 | |a GBV_ILN_4338 | ||
912 | |a GBV_ILN_4367 | ||
912 | |a GBV_ILN_4700 | ||
951 | |a AR | ||
952 | |d 15 |j 2021 |e 10 |h EC24-EC28 |
author_variant |
a k ak d d dd b n bn p b pb s p sp t k tk |
---|---|
matchkey_str |
article:0973709X:2021----::muoitceiaepesoovsuaedteilrwhatrnvrasraepteilepamadtascainihitlg |
hierarchy_sort_str |
2021 |
publishDate |
2021 |
allfields |
10.7860/JCDR/2021/49501.15533 doi (DE-627)DOAJ007611137 (DE-599)DOAJ7c71bd9fb2a04965a7736b7ad76e4eb2 DE-627 ger DE-627 rakwb eng Asaranti Kar verfasserin aut Immunohistochemical Expression of Vascular Endothelial Growth Factor in Ovarian Surface Epithelial Neoplasms and its Association with Histological Type, Grade, Clinical Stage and Tumour Metastasis 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Introduction: Ovarian carcinoma is one of the most common gynaecologic cancers and remains the leading cause of death as the patients are diagnosed at the advanced stage of the disease. Vascular Endothelial Growth Factor (VEGF), a promoter of angiogenesis, participates in multiple mechanisms to promote ovarian cancer cell growth, angiopoiesis and distant metastasis. So, it is a promising target for antiangiogenic therapy in management and downstaging of ovarian cancer. Aim: To evaluate the immunohistochemical expression of VEGF in different surface epithelial neoplasms of ovary and compare it with histological type, grade and stage in malignant cases. Materials and Methods: This was an observational cross-sectional study conducted from August 2018 to January 2020. Total 50 consecutive cases of surface epithelial ovarian neoplasms received in Pathology Department of Srirama Chandra Bhanja (SCB) Medical College, Cuttack were examined for expression of VEGF by Immunohistochemistry (IHC). Data was examined to find association of VEGF expression with demographic profile, grade, stage and were analysed statistically using Statistical Package for the Social Sciences (SPSS) software version 21.0. Statistical significance was tested by using Pearson’s chi-square test. The p<0.05 was considered significant. Results: Total 50 cases of ovarian surface epithelial neoplasms of different types and grade were included in the study. A 42 of the 50 cases (84%) showed VEGF expression. Out of the 42 positive cases, 18 were high VEGF expressors and 24 were low VEGF expressors. The VEGF expression was significantly higher in carcinomas as compared to benign and borderline neoplasms and also in high grade malignancies in comparison to low grade (p≤0.001). Conclusion: The study shows that the differential expression of VEGF in different ovarian epithelial neoplasms which can be a diagnostic and prognostic tool and can be applied as a VEGF targeted therapy in certain group of patients. angiogenesis immunohistochemistry ovarian epithelial tumours targeted therapy Medicine R Debasmita Das verfasserin aut Bhagyalaxmi Nayak verfasserin aut Pallavi Bhuyan verfasserin aut Sasmita Panda verfasserin aut Tushar Kar verfasserin aut In Journal of Clinical and Diagnostic Research JCDR Research and Publications Private Limited, 2009 15(2021), 10, Seite EC24-EC28 (DE-627)789478048 (DE-600)2775283-5 0973709X nnns volume:15 year:2021 number:10 pages:EC24-EC28 https://doi.org/10.7860/JCDR/2021/49501.15533 kostenfrei https://doaj.org/article/7c71bd9fb2a04965a7736b7ad76e4eb2 kostenfrei https://jcdr.net/articles/PDF/15533/49501_CE[Ra1]_F[SH]_PF1(JY_RK)_PFA(SC_SS)_PN(KM).pdf kostenfrei https://doaj.org/toc/2249-782X Journal toc kostenfrei https://doaj.org/toc/0973-709X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 15 2021 10 EC24-EC28 |
spelling |
10.7860/JCDR/2021/49501.15533 doi (DE-627)DOAJ007611137 (DE-599)DOAJ7c71bd9fb2a04965a7736b7ad76e4eb2 DE-627 ger DE-627 rakwb eng Asaranti Kar verfasserin aut Immunohistochemical Expression of Vascular Endothelial Growth Factor in Ovarian Surface Epithelial Neoplasms and its Association with Histological Type, Grade, Clinical Stage and Tumour Metastasis 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Introduction: Ovarian carcinoma is one of the most common gynaecologic cancers and remains the leading cause of death as the patients are diagnosed at the advanced stage of the disease. Vascular Endothelial Growth Factor (VEGF), a promoter of angiogenesis, participates in multiple mechanisms to promote ovarian cancer cell growth, angiopoiesis and distant metastasis. So, it is a promising target for antiangiogenic therapy in management and downstaging of ovarian cancer. Aim: To evaluate the immunohistochemical expression of VEGF in different surface epithelial neoplasms of ovary and compare it with histological type, grade and stage in malignant cases. Materials and Methods: This was an observational cross-sectional study conducted from August 2018 to January 2020. Total 50 consecutive cases of surface epithelial ovarian neoplasms received in Pathology Department of Srirama Chandra Bhanja (SCB) Medical College, Cuttack were examined for expression of VEGF by Immunohistochemistry (IHC). Data was examined to find association of VEGF expression with demographic profile, grade, stage and were analysed statistically using Statistical Package for the Social Sciences (SPSS) software version 21.0. Statistical significance was tested by using Pearson’s chi-square test. The p<0.05 was considered significant. Results: Total 50 cases of ovarian surface epithelial neoplasms of different types and grade were included in the study. A 42 of the 50 cases (84%) showed VEGF expression. Out of the 42 positive cases, 18 were high VEGF expressors and 24 were low VEGF expressors. The VEGF expression was significantly higher in carcinomas as compared to benign and borderline neoplasms and also in high grade malignancies in comparison to low grade (p≤0.001). Conclusion: The study shows that the differential expression of VEGF in different ovarian epithelial neoplasms which can be a diagnostic and prognostic tool and can be applied as a VEGF targeted therapy in certain group of patients. angiogenesis immunohistochemistry ovarian epithelial tumours targeted therapy Medicine R Debasmita Das verfasserin aut Bhagyalaxmi Nayak verfasserin aut Pallavi Bhuyan verfasserin aut Sasmita Panda verfasserin aut Tushar Kar verfasserin aut In Journal of Clinical and Diagnostic Research JCDR Research and Publications Private Limited, 2009 15(2021), 10, Seite EC24-EC28 (DE-627)789478048 (DE-600)2775283-5 0973709X nnns volume:15 year:2021 number:10 pages:EC24-EC28 https://doi.org/10.7860/JCDR/2021/49501.15533 kostenfrei https://doaj.org/article/7c71bd9fb2a04965a7736b7ad76e4eb2 kostenfrei https://jcdr.net/articles/PDF/15533/49501_CE[Ra1]_F[SH]_PF1(JY_RK)_PFA(SC_SS)_PN(KM).pdf kostenfrei https://doaj.org/toc/2249-782X Journal toc kostenfrei https://doaj.org/toc/0973-709X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 15 2021 10 EC24-EC28 |
allfields_unstemmed |
10.7860/JCDR/2021/49501.15533 doi (DE-627)DOAJ007611137 (DE-599)DOAJ7c71bd9fb2a04965a7736b7ad76e4eb2 DE-627 ger DE-627 rakwb eng Asaranti Kar verfasserin aut Immunohistochemical Expression of Vascular Endothelial Growth Factor in Ovarian Surface Epithelial Neoplasms and its Association with Histological Type, Grade, Clinical Stage and Tumour Metastasis 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Introduction: Ovarian carcinoma is one of the most common gynaecologic cancers and remains the leading cause of death as the patients are diagnosed at the advanced stage of the disease. Vascular Endothelial Growth Factor (VEGF), a promoter of angiogenesis, participates in multiple mechanisms to promote ovarian cancer cell growth, angiopoiesis and distant metastasis. So, it is a promising target for antiangiogenic therapy in management and downstaging of ovarian cancer. Aim: To evaluate the immunohistochemical expression of VEGF in different surface epithelial neoplasms of ovary and compare it with histological type, grade and stage in malignant cases. Materials and Methods: This was an observational cross-sectional study conducted from August 2018 to January 2020. Total 50 consecutive cases of surface epithelial ovarian neoplasms received in Pathology Department of Srirama Chandra Bhanja (SCB) Medical College, Cuttack were examined for expression of VEGF by Immunohistochemistry (IHC). Data was examined to find association of VEGF expression with demographic profile, grade, stage and were analysed statistically using Statistical Package for the Social Sciences (SPSS) software version 21.0. Statistical significance was tested by using Pearson’s chi-square test. The p<0.05 was considered significant. Results: Total 50 cases of ovarian surface epithelial neoplasms of different types and grade were included in the study. A 42 of the 50 cases (84%) showed VEGF expression. Out of the 42 positive cases, 18 were high VEGF expressors and 24 were low VEGF expressors. The VEGF expression was significantly higher in carcinomas as compared to benign and borderline neoplasms and also in high grade malignancies in comparison to low grade (p≤0.001). Conclusion: The study shows that the differential expression of VEGF in different ovarian epithelial neoplasms which can be a diagnostic and prognostic tool and can be applied as a VEGF targeted therapy in certain group of patients. angiogenesis immunohistochemistry ovarian epithelial tumours targeted therapy Medicine R Debasmita Das verfasserin aut Bhagyalaxmi Nayak verfasserin aut Pallavi Bhuyan verfasserin aut Sasmita Panda verfasserin aut Tushar Kar verfasserin aut In Journal of Clinical and Diagnostic Research JCDR Research and Publications Private Limited, 2009 15(2021), 10, Seite EC24-EC28 (DE-627)789478048 (DE-600)2775283-5 0973709X nnns volume:15 year:2021 number:10 pages:EC24-EC28 https://doi.org/10.7860/JCDR/2021/49501.15533 kostenfrei https://doaj.org/article/7c71bd9fb2a04965a7736b7ad76e4eb2 kostenfrei https://jcdr.net/articles/PDF/15533/49501_CE[Ra1]_F[SH]_PF1(JY_RK)_PFA(SC_SS)_PN(KM).pdf kostenfrei https://doaj.org/toc/2249-782X Journal toc kostenfrei https://doaj.org/toc/0973-709X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 15 2021 10 EC24-EC28 |
allfieldsGer |
10.7860/JCDR/2021/49501.15533 doi (DE-627)DOAJ007611137 (DE-599)DOAJ7c71bd9fb2a04965a7736b7ad76e4eb2 DE-627 ger DE-627 rakwb eng Asaranti Kar verfasserin aut Immunohistochemical Expression of Vascular Endothelial Growth Factor in Ovarian Surface Epithelial Neoplasms and its Association with Histological Type, Grade, Clinical Stage and Tumour Metastasis 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Introduction: Ovarian carcinoma is one of the most common gynaecologic cancers and remains the leading cause of death as the patients are diagnosed at the advanced stage of the disease. Vascular Endothelial Growth Factor (VEGF), a promoter of angiogenesis, participates in multiple mechanisms to promote ovarian cancer cell growth, angiopoiesis and distant metastasis. So, it is a promising target for antiangiogenic therapy in management and downstaging of ovarian cancer. Aim: To evaluate the immunohistochemical expression of VEGF in different surface epithelial neoplasms of ovary and compare it with histological type, grade and stage in malignant cases. Materials and Methods: This was an observational cross-sectional study conducted from August 2018 to January 2020. Total 50 consecutive cases of surface epithelial ovarian neoplasms received in Pathology Department of Srirama Chandra Bhanja (SCB) Medical College, Cuttack were examined for expression of VEGF by Immunohistochemistry (IHC). Data was examined to find association of VEGF expression with demographic profile, grade, stage and were analysed statistically using Statistical Package for the Social Sciences (SPSS) software version 21.0. Statistical significance was tested by using Pearson’s chi-square test. The p<0.05 was considered significant. Results: Total 50 cases of ovarian surface epithelial neoplasms of different types and grade were included in the study. A 42 of the 50 cases (84%) showed VEGF expression. Out of the 42 positive cases, 18 were high VEGF expressors and 24 were low VEGF expressors. The VEGF expression was significantly higher in carcinomas as compared to benign and borderline neoplasms and also in high grade malignancies in comparison to low grade (p≤0.001). Conclusion: The study shows that the differential expression of VEGF in different ovarian epithelial neoplasms which can be a diagnostic and prognostic tool and can be applied as a VEGF targeted therapy in certain group of patients. angiogenesis immunohistochemistry ovarian epithelial tumours targeted therapy Medicine R Debasmita Das verfasserin aut Bhagyalaxmi Nayak verfasserin aut Pallavi Bhuyan verfasserin aut Sasmita Panda verfasserin aut Tushar Kar verfasserin aut In Journal of Clinical and Diagnostic Research JCDR Research and Publications Private Limited, 2009 15(2021), 10, Seite EC24-EC28 (DE-627)789478048 (DE-600)2775283-5 0973709X nnns volume:15 year:2021 number:10 pages:EC24-EC28 https://doi.org/10.7860/JCDR/2021/49501.15533 kostenfrei https://doaj.org/article/7c71bd9fb2a04965a7736b7ad76e4eb2 kostenfrei https://jcdr.net/articles/PDF/15533/49501_CE[Ra1]_F[SH]_PF1(JY_RK)_PFA(SC_SS)_PN(KM).pdf kostenfrei https://doaj.org/toc/2249-782X Journal toc kostenfrei https://doaj.org/toc/0973-709X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 15 2021 10 EC24-EC28 |
allfieldsSound |
10.7860/JCDR/2021/49501.15533 doi (DE-627)DOAJ007611137 (DE-599)DOAJ7c71bd9fb2a04965a7736b7ad76e4eb2 DE-627 ger DE-627 rakwb eng Asaranti Kar verfasserin aut Immunohistochemical Expression of Vascular Endothelial Growth Factor in Ovarian Surface Epithelial Neoplasms and its Association with Histological Type, Grade, Clinical Stage and Tumour Metastasis 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Introduction: Ovarian carcinoma is one of the most common gynaecologic cancers and remains the leading cause of death as the patients are diagnosed at the advanced stage of the disease. Vascular Endothelial Growth Factor (VEGF), a promoter of angiogenesis, participates in multiple mechanisms to promote ovarian cancer cell growth, angiopoiesis and distant metastasis. So, it is a promising target for antiangiogenic therapy in management and downstaging of ovarian cancer. Aim: To evaluate the immunohistochemical expression of VEGF in different surface epithelial neoplasms of ovary and compare it with histological type, grade and stage in malignant cases. Materials and Methods: This was an observational cross-sectional study conducted from August 2018 to January 2020. Total 50 consecutive cases of surface epithelial ovarian neoplasms received in Pathology Department of Srirama Chandra Bhanja (SCB) Medical College, Cuttack were examined for expression of VEGF by Immunohistochemistry (IHC). Data was examined to find association of VEGF expression with demographic profile, grade, stage and were analysed statistically using Statistical Package for the Social Sciences (SPSS) software version 21.0. Statistical significance was tested by using Pearson’s chi-square test. The p<0.05 was considered significant. Results: Total 50 cases of ovarian surface epithelial neoplasms of different types and grade were included in the study. A 42 of the 50 cases (84%) showed VEGF expression. Out of the 42 positive cases, 18 were high VEGF expressors and 24 were low VEGF expressors. The VEGF expression was significantly higher in carcinomas as compared to benign and borderline neoplasms and also in high grade malignancies in comparison to low grade (p≤0.001). Conclusion: The study shows that the differential expression of VEGF in different ovarian epithelial neoplasms which can be a diagnostic and prognostic tool and can be applied as a VEGF targeted therapy in certain group of patients. angiogenesis immunohistochemistry ovarian epithelial tumours targeted therapy Medicine R Debasmita Das verfasserin aut Bhagyalaxmi Nayak verfasserin aut Pallavi Bhuyan verfasserin aut Sasmita Panda verfasserin aut Tushar Kar verfasserin aut In Journal of Clinical and Diagnostic Research JCDR Research and Publications Private Limited, 2009 15(2021), 10, Seite EC24-EC28 (DE-627)789478048 (DE-600)2775283-5 0973709X nnns volume:15 year:2021 number:10 pages:EC24-EC28 https://doi.org/10.7860/JCDR/2021/49501.15533 kostenfrei https://doaj.org/article/7c71bd9fb2a04965a7736b7ad76e4eb2 kostenfrei https://jcdr.net/articles/PDF/15533/49501_CE[Ra1]_F[SH]_PF1(JY_RK)_PFA(SC_SS)_PN(KM).pdf kostenfrei https://doaj.org/toc/2249-782X Journal toc kostenfrei https://doaj.org/toc/0973-709X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 15 2021 10 EC24-EC28 |
language |
English |
source |
In Journal of Clinical and Diagnostic Research 15(2021), 10, Seite EC24-EC28 volume:15 year:2021 number:10 pages:EC24-EC28 |
sourceStr |
In Journal of Clinical and Diagnostic Research 15(2021), 10, Seite EC24-EC28 volume:15 year:2021 number:10 pages:EC24-EC28 |
format_phy_str_mv |
Article |
institution |
findex.gbv.de |
topic_facet |
angiogenesis immunohistochemistry ovarian epithelial tumours targeted therapy Medicine R |
isfreeaccess_bool |
true |
container_title |
Journal of Clinical and Diagnostic Research |
authorswithroles_txt_mv |
Asaranti Kar @@aut@@ Debasmita Das @@aut@@ Bhagyalaxmi Nayak @@aut@@ Pallavi Bhuyan @@aut@@ Sasmita Panda @@aut@@ Tushar Kar @@aut@@ |
publishDateDaySort_date |
2021-01-01T00:00:00Z |
hierarchy_top_id |
789478048 |
id |
DOAJ007611137 |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ007611137</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230502113843.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230225s2021 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.7860/JCDR/2021/49501.15533</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ007611137</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ7c71bd9fb2a04965a7736b7ad76e4eb2</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Asaranti Kar</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Immunohistochemical Expression of Vascular Endothelial Growth Factor in Ovarian Surface Epithelial Neoplasms and its Association with Histological Type, Grade, Clinical Stage and Tumour Metastasis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Introduction: Ovarian carcinoma is one of the most common gynaecologic cancers and remains the leading cause of death as the patients are diagnosed at the advanced stage of the disease. Vascular Endothelial Growth Factor (VEGF), a promoter of angiogenesis, participates in multiple mechanisms to promote ovarian cancer cell growth, angiopoiesis and distant metastasis. So, it is a promising target for antiangiogenic therapy in management and downstaging of ovarian cancer. Aim: To evaluate the immunohistochemical expression of VEGF in different surface epithelial neoplasms of ovary and compare it with histological type, grade and stage in malignant cases. Materials and Methods: This was an observational cross-sectional study conducted from August 2018 to January 2020. Total 50 consecutive cases of surface epithelial ovarian neoplasms received in Pathology Department of Srirama Chandra Bhanja (SCB) Medical College, Cuttack were examined for expression of VEGF by Immunohistochemistry (IHC). Data was examined to find association of VEGF expression with demographic profile, grade, stage and were analysed statistically using Statistical Package for the Social Sciences (SPSS) software version 21.0. Statistical significance was tested by using Pearson’s chi-square test. The p<0.05 was considered significant. Results: Total 50 cases of ovarian surface epithelial neoplasms of different types and grade were included in the study. A 42 of the 50 cases (84%) showed VEGF expression. Out of the 42 positive cases, 18 were high VEGF expressors and 24 were low VEGF expressors. The VEGF expression was significantly higher in carcinomas as compared to benign and borderline neoplasms and also in high grade malignancies in comparison to low grade (p≤0.001). Conclusion: The study shows that the differential expression of VEGF in different ovarian epithelial neoplasms which can be a diagnostic and prognostic tool and can be applied as a VEGF targeted therapy in certain group of patients.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">angiogenesis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">immunohistochemistry</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">ovarian epithelial tumours</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">targeted therapy</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Debasmita Das</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Bhagyalaxmi Nayak</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Pallavi Bhuyan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sasmita Panda</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Tushar Kar</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Journal of Clinical and Diagnostic Research</subfield><subfield code="d">JCDR Research and Publications Private Limited, 2009</subfield><subfield code="g">15(2021), 10, Seite EC24-EC28</subfield><subfield code="w">(DE-627)789478048</subfield><subfield code="w">(DE-600)2775283-5</subfield><subfield code="x">0973709X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:15</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:10</subfield><subfield code="g">pages:EC24-EC28</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.7860/JCDR/2021/49501.15533</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/7c71bd9fb2a04965a7736b7ad76e4eb2</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://jcdr.net/articles/PDF/15533/49501_CE[Ra1]_F[SH]_PF1(JY_RK)_PFA(SC_SS)_PN(KM).pdf</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2249-782X</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/0973-709X</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">15</subfield><subfield code="j">2021</subfield><subfield code="e">10</subfield><subfield code="h">EC24-EC28</subfield></datafield></record></collection>
|
author |
Asaranti Kar |
spellingShingle |
Asaranti Kar misc angiogenesis misc immunohistochemistry misc ovarian epithelial tumours misc targeted therapy misc Medicine misc R Immunohistochemical Expression of Vascular Endothelial Growth Factor in Ovarian Surface Epithelial Neoplasms and its Association with Histological Type, Grade, Clinical Stage and Tumour Metastasis |
authorStr |
Asaranti Kar |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)789478048 |
format |
electronic Article |
delete_txt_mv |
keep |
author_role |
aut aut aut aut aut aut |
collection |
DOAJ |
remote_str |
true |
illustrated |
Not Illustrated |
issn |
0973709X |
topic_title |
Immunohistochemical Expression of Vascular Endothelial Growth Factor in Ovarian Surface Epithelial Neoplasms and its Association with Histological Type, Grade, Clinical Stage and Tumour Metastasis angiogenesis immunohistochemistry ovarian epithelial tumours targeted therapy |
topic |
misc angiogenesis misc immunohistochemistry misc ovarian epithelial tumours misc targeted therapy misc Medicine misc R |
topic_unstemmed |
misc angiogenesis misc immunohistochemistry misc ovarian epithelial tumours misc targeted therapy misc Medicine misc R |
topic_browse |
misc angiogenesis misc immunohistochemistry misc ovarian epithelial tumours misc targeted therapy misc Medicine misc R |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
cr |
hierarchy_parent_title |
Journal of Clinical and Diagnostic Research |
hierarchy_parent_id |
789478048 |
hierarchy_top_title |
Journal of Clinical and Diagnostic Research |
isfreeaccess_txt |
true |
familylinks_str_mv |
(DE-627)789478048 (DE-600)2775283-5 |
title |
Immunohistochemical Expression of Vascular Endothelial Growth Factor in Ovarian Surface Epithelial Neoplasms and its Association with Histological Type, Grade, Clinical Stage and Tumour Metastasis |
ctrlnum |
(DE-627)DOAJ007611137 (DE-599)DOAJ7c71bd9fb2a04965a7736b7ad76e4eb2 |
title_full |
Immunohistochemical Expression of Vascular Endothelial Growth Factor in Ovarian Surface Epithelial Neoplasms and its Association with Histological Type, Grade, Clinical Stage and Tumour Metastasis |
author_sort |
Asaranti Kar |
journal |
Journal of Clinical and Diagnostic Research |
journalStr |
Journal of Clinical and Diagnostic Research |
lang_code |
eng |
isOA_bool |
true |
recordtype |
marc |
publishDateSort |
2021 |
contenttype_str_mv |
txt |
author_browse |
Asaranti Kar Debasmita Das Bhagyalaxmi Nayak Pallavi Bhuyan Sasmita Panda Tushar Kar |
container_volume |
15 |
format_se |
Elektronische Aufsätze |
author-letter |
Asaranti Kar |
doi_str_mv |
10.7860/JCDR/2021/49501.15533 |
author2-role |
verfasserin |
title_sort |
immunohistochemical expression of vascular endothelial growth factor in ovarian surface epithelial neoplasms and its association with histological type, grade, clinical stage and tumour metastasis |
title_auth |
Immunohistochemical Expression of Vascular Endothelial Growth Factor in Ovarian Surface Epithelial Neoplasms and its Association with Histological Type, Grade, Clinical Stage and Tumour Metastasis |
abstract |
Introduction: Ovarian carcinoma is one of the most common gynaecologic cancers and remains the leading cause of death as the patients are diagnosed at the advanced stage of the disease. Vascular Endothelial Growth Factor (VEGF), a promoter of angiogenesis, participates in multiple mechanisms to promote ovarian cancer cell growth, angiopoiesis and distant metastasis. So, it is a promising target for antiangiogenic therapy in management and downstaging of ovarian cancer. Aim: To evaluate the immunohistochemical expression of VEGF in different surface epithelial neoplasms of ovary and compare it with histological type, grade and stage in malignant cases. Materials and Methods: This was an observational cross-sectional study conducted from August 2018 to January 2020. Total 50 consecutive cases of surface epithelial ovarian neoplasms received in Pathology Department of Srirama Chandra Bhanja (SCB) Medical College, Cuttack were examined for expression of VEGF by Immunohistochemistry (IHC). Data was examined to find association of VEGF expression with demographic profile, grade, stage and were analysed statistically using Statistical Package for the Social Sciences (SPSS) software version 21.0. Statistical significance was tested by using Pearson’s chi-square test. The p<0.05 was considered significant. Results: Total 50 cases of ovarian surface epithelial neoplasms of different types and grade were included in the study. A 42 of the 50 cases (84%) showed VEGF expression. Out of the 42 positive cases, 18 were high VEGF expressors and 24 were low VEGF expressors. The VEGF expression was significantly higher in carcinomas as compared to benign and borderline neoplasms and also in high grade malignancies in comparison to low grade (p≤0.001). Conclusion: The study shows that the differential expression of VEGF in different ovarian epithelial neoplasms which can be a diagnostic and prognostic tool and can be applied as a VEGF targeted therapy in certain group of patients. |
abstractGer |
Introduction: Ovarian carcinoma is one of the most common gynaecologic cancers and remains the leading cause of death as the patients are diagnosed at the advanced stage of the disease. Vascular Endothelial Growth Factor (VEGF), a promoter of angiogenesis, participates in multiple mechanisms to promote ovarian cancer cell growth, angiopoiesis and distant metastasis. So, it is a promising target for antiangiogenic therapy in management and downstaging of ovarian cancer. Aim: To evaluate the immunohistochemical expression of VEGF in different surface epithelial neoplasms of ovary and compare it with histological type, grade and stage in malignant cases. Materials and Methods: This was an observational cross-sectional study conducted from August 2018 to January 2020. Total 50 consecutive cases of surface epithelial ovarian neoplasms received in Pathology Department of Srirama Chandra Bhanja (SCB) Medical College, Cuttack were examined for expression of VEGF by Immunohistochemistry (IHC). Data was examined to find association of VEGF expression with demographic profile, grade, stage and were analysed statistically using Statistical Package for the Social Sciences (SPSS) software version 21.0. Statistical significance was tested by using Pearson’s chi-square test. The p<0.05 was considered significant. Results: Total 50 cases of ovarian surface epithelial neoplasms of different types and grade were included in the study. A 42 of the 50 cases (84%) showed VEGF expression. Out of the 42 positive cases, 18 were high VEGF expressors and 24 were low VEGF expressors. The VEGF expression was significantly higher in carcinomas as compared to benign and borderline neoplasms and also in high grade malignancies in comparison to low grade (p≤0.001). Conclusion: The study shows that the differential expression of VEGF in different ovarian epithelial neoplasms which can be a diagnostic and prognostic tool and can be applied as a VEGF targeted therapy in certain group of patients. |
abstract_unstemmed |
Introduction: Ovarian carcinoma is one of the most common gynaecologic cancers and remains the leading cause of death as the patients are diagnosed at the advanced stage of the disease. Vascular Endothelial Growth Factor (VEGF), a promoter of angiogenesis, participates in multiple mechanisms to promote ovarian cancer cell growth, angiopoiesis and distant metastasis. So, it is a promising target for antiangiogenic therapy in management and downstaging of ovarian cancer. Aim: To evaluate the immunohistochemical expression of VEGF in different surface epithelial neoplasms of ovary and compare it with histological type, grade and stage in malignant cases. Materials and Methods: This was an observational cross-sectional study conducted from August 2018 to January 2020. Total 50 consecutive cases of surface epithelial ovarian neoplasms received in Pathology Department of Srirama Chandra Bhanja (SCB) Medical College, Cuttack were examined for expression of VEGF by Immunohistochemistry (IHC). Data was examined to find association of VEGF expression with demographic profile, grade, stage and were analysed statistically using Statistical Package for the Social Sciences (SPSS) software version 21.0. Statistical significance was tested by using Pearson’s chi-square test. The p<0.05 was considered significant. Results: Total 50 cases of ovarian surface epithelial neoplasms of different types and grade were included in the study. A 42 of the 50 cases (84%) showed VEGF expression. Out of the 42 positive cases, 18 were high VEGF expressors and 24 were low VEGF expressors. The VEGF expression was significantly higher in carcinomas as compared to benign and borderline neoplasms and also in high grade malignancies in comparison to low grade (p≤0.001). Conclusion: The study shows that the differential expression of VEGF in different ovarian epithelial neoplasms which can be a diagnostic and prognostic tool and can be applied as a VEGF targeted therapy in certain group of patients. |
collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 |
container_issue |
10 |
title_short |
Immunohistochemical Expression of Vascular Endothelial Growth Factor in Ovarian Surface Epithelial Neoplasms and its Association with Histological Type, Grade, Clinical Stage and Tumour Metastasis |
url |
https://doi.org/10.7860/JCDR/2021/49501.15533 https://doaj.org/article/7c71bd9fb2a04965a7736b7ad76e4eb2 https://jcdr.net/articles/PDF/15533/49501_CE[Ra1]_F[SH]_PF1(JY_RK)_PFA(SC_SS)_PN(KM).pdf https://doaj.org/toc/2249-782X https://doaj.org/toc/0973-709X |
remote_bool |
true |
author2 |
Debasmita Das Bhagyalaxmi Nayak Pallavi Bhuyan Sasmita Panda Tushar Kar |
author2Str |
Debasmita Das Bhagyalaxmi Nayak Pallavi Bhuyan Sasmita Panda Tushar Kar |
ppnlink |
789478048 |
mediatype_str_mv |
c |
isOA_txt |
true |
hochschulschrift_bool |
false |
doi_str |
10.7860/JCDR/2021/49501.15533 |
up_date |
2024-07-04T02:12:37.316Z |
_version_ |
1803612750943879168 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ007611137</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230502113843.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230225s2021 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.7860/JCDR/2021/49501.15533</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ007611137</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ7c71bd9fb2a04965a7736b7ad76e4eb2</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Asaranti Kar</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Immunohistochemical Expression of Vascular Endothelial Growth Factor in Ovarian Surface Epithelial Neoplasms and its Association with Histological Type, Grade, Clinical Stage and Tumour Metastasis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Introduction: Ovarian carcinoma is one of the most common gynaecologic cancers and remains the leading cause of death as the patients are diagnosed at the advanced stage of the disease. Vascular Endothelial Growth Factor (VEGF), a promoter of angiogenesis, participates in multiple mechanisms to promote ovarian cancer cell growth, angiopoiesis and distant metastasis. So, it is a promising target for antiangiogenic therapy in management and downstaging of ovarian cancer. Aim: To evaluate the immunohistochemical expression of VEGF in different surface epithelial neoplasms of ovary and compare it with histological type, grade and stage in malignant cases. Materials and Methods: This was an observational cross-sectional study conducted from August 2018 to January 2020. Total 50 consecutive cases of surface epithelial ovarian neoplasms received in Pathology Department of Srirama Chandra Bhanja (SCB) Medical College, Cuttack were examined for expression of VEGF by Immunohistochemistry (IHC). Data was examined to find association of VEGF expression with demographic profile, grade, stage and were analysed statistically using Statistical Package for the Social Sciences (SPSS) software version 21.0. Statistical significance was tested by using Pearson’s chi-square test. The p<0.05 was considered significant. Results: Total 50 cases of ovarian surface epithelial neoplasms of different types and grade were included in the study. A 42 of the 50 cases (84%) showed VEGF expression. Out of the 42 positive cases, 18 were high VEGF expressors and 24 were low VEGF expressors. The VEGF expression was significantly higher in carcinomas as compared to benign and borderline neoplasms and also in high grade malignancies in comparison to low grade (p≤0.001). Conclusion: The study shows that the differential expression of VEGF in different ovarian epithelial neoplasms which can be a diagnostic and prognostic tool and can be applied as a VEGF targeted therapy in certain group of patients.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">angiogenesis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">immunohistochemistry</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">ovarian epithelial tumours</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">targeted therapy</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Debasmita Das</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Bhagyalaxmi Nayak</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Pallavi Bhuyan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sasmita Panda</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Tushar Kar</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Journal of Clinical and Diagnostic Research</subfield><subfield code="d">JCDR Research and Publications Private Limited, 2009</subfield><subfield code="g">15(2021), 10, Seite EC24-EC28</subfield><subfield code="w">(DE-627)789478048</subfield><subfield code="w">(DE-600)2775283-5</subfield><subfield code="x">0973709X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:15</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:10</subfield><subfield code="g">pages:EC24-EC28</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.7860/JCDR/2021/49501.15533</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/7c71bd9fb2a04965a7736b7ad76e4eb2</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://jcdr.net/articles/PDF/15533/49501_CE[Ra1]_F[SH]_PF1(JY_RK)_PFA(SC_SS)_PN(KM).pdf</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2249-782X</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/0973-709X</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">15</subfield><subfield code="j">2021</subfield><subfield code="e">10</subfield><subfield code="h">EC24-EC28</subfield></datafield></record></collection>
|
score |
7.4001293 |